J Intern Med 1994, 235:245–248 PubMed 42 Casadei R, Tomassetti P

J Intern Med 1994, 235:245–248.PubMed 42. Casadei R, Tomassetti P, Rossi C, la Donna M, Migliori M, Marrano D: Treatment of metastatic

glucagonoma to the liver: case report and literature review. Ital J Gastroenterol Hepatol 1999, 31:308–312.PubMed 43. Tomassetti P, Migliori M, PS-341 molecular weight Corinaldesi R, Gullo L: Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000, 14:557–560.PubMed 44. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV: The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore) 1996, 75:53–63. 45. Grozinsky-Glasberg S, Grossman AB, Korbonits M: The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol 2008, 286:238–50.PubMed 46. Appetecchia

M, Ferretti E, Carducci M, Izzo F, Carpanese L, Marandino F, Terzoli E: Malignant glucagonoma. New options of treatment. J Exp Clin Cancer Res 2006, 25:135–9.PubMed 47. Soga J, Yakuwa Y: Somatostatinoma/Dibutyryl-cAMP concentration inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999, 18:13–22.PubMed 48. Angeletti S, Corleto VD, Schillaci O, Marignani M, Annibale B, Moretti A, Silecchia G, Scopinaro F, Basso N, Bordi C, Delle LY2874455 research buy Fave G: Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998, 42:792–794.PubMed 49. Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ: Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg 2007, 12:382–93. 50. Song S, Shi R, Li B, Liu Y: Diagnosis and Treatment of Pancreatic Vasoactive Intestinal Peptide Endocrine Tumors. Pancreas 2009,38(7):811–4.PubMed 51. Nakayama S, Yokote T, Kobayashi K, Hirata Y, Hiraiwa T, Komoto I, Miyakoshi K, Yamakawa Y, Takubo T, Tsuji M, Imamura M, Hanafusa T: VIPoma with expression of both VIP and VPAC1 receptors

in a patient with WDHA syndrome. Endocrine 2009, 35:143–6.PubMed 52. Schally AV: Oncological applications of somatostatin analogues. Cancer Res 1988, 48:6977–6985.PubMed 53. Pollak MN, Schally AV: Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998, 217:143–152.PubMed 54. Weckbecker to G, Raulf F, Stolz B, Bruns C: Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993, 60:245–264.PubMed 55. Froidevaux S, Eberle AN: Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002, 66:161–183.PubMed 56. Schally AV, Nagy A: Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004, 15:300–310.PubMed 57. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C: Antitumor effects of somatostatin. Mol Cell Endocrinol 2008, 286:230–7.PubMed 58.

Comments are closed.